Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15067925 | 0.99 | ADORA2B (0.40) | ADORA2BADORA3MEN1HTTKMT2A | |
| SCHEMBL15068198 | 0.97 | ADORA2B (0.37) | ADORA2BADORA3MEN1HTTKMT2A | |
| SCHEMBL15068195 | 0.94 | ADORA2B (0.37) | ADORA2BADORA3MEN1HTTKMT2A | |
| SCHEMBL15068073 | 0.93 | MEN1 (0.36) | ADORA2BADORA3MEN1HTTKMT2A | |
| SCHEMBL15067912 | 0.93 | MEN1 (0.36) | ADORA2BADORA3MEN1HTTKMT2A | |
| SCHEMBL15067654 | 0.88 | ADORA2B (0.40) | ADORA2BADORA3MEN1HTTKMT2A | |
| SCHEMBL15067926 | 0.88 | ADORA2B (0.40) | ADORA2BADORA3MEN1HTTKMT2A | |
| SCHEMBL15067287 | 0.87 | MAPT (0.35) | ADORA2BADORA3MEN1KMT2AADORA2A | |
| SCHEMBL15067410 | 0.87 | MAPT (0.35) | HTTHSD17B10GLATP53LMNA | |
| SCHEMBL15067731 | 0.87 | MAPT (0.35) | HTTHSD17B10GLATP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797930-B1 | FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-07-13 | — | — | EP | claimed |
| US-9206177-B2 | Substituted dimeric quinazoline-2,4-diones as FGF receptor agonists | SANOFI (FR) | 2015-12-08 | — | — | US | claimed |
| US-20140378483-A1 | FGF Receptor (FGFR) Agonist Dimeric Compounds, Process for the Preparation Thereof and Therapeutic Use Thereof | SANOFI (FR) | 2014-12-25 | — | — | US | claimed |
| EP-2797930-B1 | FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-9206177-B2 | Substituted dimeric quinazoline-2,4-diones as FGF receptor agonists | SANOFI (FR) | 2015-12-08 | — | — | US | disclosed |
| US-20140378483-A1 | FGF Receptor (FGFR) Agonist Dimeric Compounds, Process for the Preparation Thereof and Therapeutic Use Thereof | SANOFI (FR) | 2014-12-25 | — | — | US | disclosed |
| EP-2797930-A1 | FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013098763-A1 | FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378483-A1 | FGF Receptor (FGFR) Agonist Dimeric Compounds, Process for the Preparation Thereof and Therapeutic Use Thereof | FGFR1, FGFR2, FGF2 | ADORA2B 1264/4885ADORA3 923/4885MEN1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.